Many women facing breast cancer surgery are concerned about lymphedema. Dr. Julie Biller says women who have sentinel lymph node biopsies, where 1-3 lymph nodes are removed, have only a 5% of risk of developing lymphedema. The risk can be even lower when an experienced surgeon does the procedure.


Genomic Health is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. The company's lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).

SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS
[ Ссылка ]

VISIT BREASTCANCERANSWERS.com FOR INFORMATIVE VIDEOS
[ Ссылка ]

SUBMIT A QUESTION
[ Ссылка ]

DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR
[ Ссылка ]

CONNECT WITH US!
Google+: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]

______

Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

свернуть